X4 Pharmaceuticals, Inc. Common Stock (XFOR)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
- Headquarters
- United States
- Employees
- 45
- Market Cap
- $377M
About X4 Pharmaceuticals, Inc. Common Stock
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
SentiSense also tracks daily options readings for X4 Pharmaceuticals, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
X4 Pharmaceuticals, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.